What is HIMS stock price target for 2026?

WallStSmart's 12-month price target for Hims Hers Health Inc is $15.27, representing 42.0% downside from the current price of $26.33.

What is HIMS stock forecast?

Hims Hers Health Inc forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

Is HIMS undervalued based on price targets?

Our DCF intrinsic value for Hims Hers Health Inc is $39.04, against a current price of $26.33. The margin of safety is 23.77%.

HIMS

Hims Hers Health Inc

NYSE: HIMS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$26.33

-5.66% today

Updated 2026-04-29

Market cap

$6.08B

P/E ratio

51.63

P/S ratio

2.59x

EPS (TTM)

$0.51

Dividend yield

—

52W range

$14 – $70

Volume

38.8M

Market cap

$6.08B

P/E ratio

51.63

P/S ratio

2.59x

EPS (TTM)

$0.51

Dividend yield

—

52W range

$14 – $70

Volume

38.8M

Hims Hers Health Inc (HIMS) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$26.33

Consensus

$29.50

+12.04%

2030 Target

$77.53

+194.45%

DCF

$39.04

+23.77% MoS

Current price

$26.33

Analyst consensus

$29.50

+12.04%

2030 Target

$77.53

+194.45%

Intrinsic (DCF)

$39.04

+23.77% MoS

14 analysts:

1 Buy11 Hold0 Sell

Management guidance

No specific CEO revenue guidance found in available materials. Company has not publicly stated explicit 2026-2030 revenue targets. Management focus appears to be on GLP-1 partnership execution (Novo Nordisk deal announced March 2026) and regulatory navigation rather than quantified revenue forecasts.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$124.04

$6.7B Rev × 4x P/S

Base case (2030)

$77.53

$6.7B Rev × 2.5x P/S

Bear case (2030)

$46.52

$6.7B Rev × 1.5x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$0.9B	$1.5B	$2.3B	$2.8B	$3.4B	$4.3B	$5.4B	$6.7B
Revenue growth	—	69.3%	59.0%	19.6%	19.2%	27.6%	26.2%	23.3%
EPS	$-0.11	$0.54	$0.51	$0.58	$0.64	$0.92	$1.24	$1.58
P/S ratio	—	—	—	2.5x	2.5x	2.5x	2.5x	2.5x
Implied price	—	—	—	$34.11	$40.31	$49.62	$65.12	$77.53

Catalysts & risks

Growth catalysts

+ FDA peptide compounding policy review (regulatory tailwind for non-GLP-1 products)

+ Novo Nordisk GLP-1 partnership expansion (Wegovy/Ozempic distribution via telehealth)

+ Margin expansion as telemedicine infrastructure scales and mix shifts to higher-margin GLP-1/prescription drugs

+ Potential acquisition of compounded peptide market share as regulatory environment clarifies

Key risks

- Regulatory restriction on compounded GLP-1 drugs (FDA enforcement on non-FDA-approved formulations)

- Heavy reliance on GLP-1 drugs creates vulnerability to pricing pressure from pharma partners and insurance

- Novo Nordisk partnership dependency — loss of partnership could severely impact growth

- Ongoing litigation and SEC investigations regarding compounded drug marketing and disclosure

- Competition from direct pharma distribution (Novo, Eli Lilly) and other telehealth platforms (Amazon Pharmacy, Mark Cuban Cost Plus Drugs)

Methodology

Hims Hers Health Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 14 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 21, 2026.